HIMS — Hims & Hers Health, Inc.

HIMS & HERS Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Grew 49% year-over-year to nearly $600 million.
• Adjusted EBITDA: Increased over 50% year-over-year to $78 million, with margins above 13%.
• Subscriber Growth: Added over 30,000 new subscribers sequentially, reflecting a year-over-year growth rate of 20%.
• Cash Flow: Generated $149 million in cash flow from operations, resulting in $79 million of free cash flow.
• Cash Position: Ended the quarter with over $1.1 billion in cash and short-term investments.

2. Strategic Updates and Business Highlights

• Subscriber Growth: Personalized solutions saw a 50% increase in subscribers year-over-year, contributing to nearly 50% revenue growth.
• Product Expansion: Launched new offerings in low testosterone and menopause, with expectations for significant revenue contributions in 2026.
• Partnerships: Engaged in discussions with Novo Nordisk for Wegovy injections and announced a partnership with Marius Pharmaceuticals for oral testosterone treatments.
• International Expansion: Acquired Zava Global, expanding reach in Europe, and preparing to enter the Canadian market.
• Diagnostic Capabilities: Set to launch comprehensive whole body lab testing by year-end, aiming to enhance proactive health management.

3. Forward Guidance and Outlook

• Q4 2025 Revenue Guidance: Expected between $605 million to $625 million, representing 26% to 30% year-over-year growth.
• Full Year 2025 Revenue Guidance: Anticipated between $2.335 billion and $2.355 billion, reflecting a 58% to 59% year-over-year increase.
• Adjusted EBITDA for Q4: Projected in the range of $55 million to $65 million, with a 10% margin at the midpoint.
• Long-term Goals: Aiming for over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.

4. Bad News, Challenges, or Points of Concern

• Transition in Sexual Health Business: Noted a shift from on-demand to daily treatment offerings, which is expected to impact growth temporarily.
• Operational Headwinds: Anticipated $20 million to $25 million revenue headwind in Q4 due to changes in fulfillment for weight loss products.
• Gross Margin Decline: Experienced a decline in gross margins to 74% due to lower revenue recognized per shipment in weight loss offerings.
• Increased G&A Costs: G&A expenses rose due to Zava integration and new leadership hires, impacting profitability metrics.

5. Notable Q&A Insights

• Diagnostic Testing Impact: Andrew Dudum emphasized that the launch of lab testing will accelerate the introduction of personalized treatments and expand into new specialties.
• Marketing Strategy: The company plans to shift its marketing approach to promote a broader range of health solutions, moving away from a focus solely on stigmatized conditions.
• International Market Dynamics: Dudum expressed confidence in the global demand for consumer-centric healthcare, noting that frustrations with access to care are consistent across markets.
• GLP-1 Solutions: Discussions with Novo Nordisk are ongoing, with a focus on expanding treatment options and ensuring affordability for consumers.

Overall, Hims & Hers reported strong growth in Q3 2025, driven by strategic expansions and new offerings, while also facing some operational challenges and market transitions that could impact short-term performance.